Comparison

iURO Oncology vs ESMO Interactive Guidelines

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

iURO Oncology

This app provides narrated simulation videos and interactive 3D models to explain uro-oncology conditions and treatments. It's designed for healthcare professionals, students, and patients to enhance understanding and communication.

Highlights
  • Narrated simulation videos for cancers
  • Explanation of treatment options
  • Interactive 3D image drawing and notes
  • 360º view of kidney anatomy
  • Email sharing of customized images
Features
Read full description

iURO Oncology is the must-have app for all uro-oncology healthcare professionals and students. The narrated simulation videos make it easy to understand and explain the different pathologies and therapies. It can be used by doctors and nurses to enhance communication with their patients. Medical students can use iURO apps to increase their knowledge and understanding of various urological and oncological topics. iURO Oncology can also be used by patients directly, to familiarize themselves with the different aspects of their oncological condition and the treatment options available. Features include: •Narrated simulation videos to explain prostate cancer, kidney cancer, bladder cancer and testicular cancer •Narrated simulation videos to explain different treatment options •Draw on picture, offering the opportunity to draw on and make personalized notes on a 3D image •Send this customized 3D image directly to patients or colleagues by email •360º image of the kidney, offering the opportunity to zoom on the 3D image from every angle iURO apps are created in consultation with urologists in order to provide a realistic representation of pathologies and therapies. iURO apps are prepared with the aim of enhancing communication and education options. If you are not a healthcare professional, please note that iURO apps support but never substitute the relation with your healthcare professional. App Management: •Scientific Director: Carlos Rioja, Hospital Royo Villanova, Zaragoza, Spain •Scientific Director: Jorge Rioja, Hospital Miguel Servet, Zaragoza, Spain •Scientific Director: Sanjeev Bandi, Mackay Urology, Mackay Australia iURO Scientific Advisory Board: Lithiasis •Olivier Traxer, University Pierre et Marie Curie Paris, France •Adrian Joyce, Spire Leeds Hospital in Roundhay, Leeds, Yorkshire, United Kingdom Benign Prostatic Hyperplasia •Jean de la Rosette, AMC University Hospital, Amsterdam, The Netherlands •Matthias Oelke, Hanover Medical School, Hanover, Germany Pelvic Floor Disorder, Functional and Female Urology •David Castro, University of La Laguna, Tenerife, Spain •Dirk De Ridder, Kliniekhoofd Urologie UZ, Leuven, Belgium Oncology •Karim Touijer, Memorial Sloan Kettering Cancer Center, New York, USA •Raul Parra, Memorial Sloan Kettering Cancer Center, New York, USA •Peter Scardino, Memorial Sloan Kettering Cancer Center, New York, USA •Pilar Laguna, AMC University Hospital, Amsterdam •Sharokh Shariat, Weill Medical College of Cornell University, New York, USA •Theo de Reijke, AMC University Hospital Amsterdam, The Netherlands •Octavio Castillo Cadiz, Clínica Indisa, Santiago, Chile •Jaime Landman, University of California Irvine, Los Angeles, USA Andrology •Eduard Garcia, University Hospital Clícic de Barcelona, Barcelona, Spain •Juan Ignacio Martinez Salamanca, University Hospital Puerta de Hierro Majadahonda, Autonomous University of Madrid, Madrid, Spain •Ignacio Moncada, Hospital La Zarzuela, Madrid, Spain •David J Ralph, St Peter’s Andrology Centre, London, United Kingdom •Nelson Bennett, Lahey Hospital and Medical Center, Burlington, USA •Rados Djinovic, Sava Perovic Foundation, Belgrade, Serbia

About

ESMO Interactive Guidelines

Access concise, practical treatment recommendations based on the latest scientific research. This app provides interactive tools, algorithms, and calculators to support healthcare professionals in decision-making and guideline navigation.

Highlights
  • Concise treatment recommendations
  • Interactive decision-making tools
  • Treatment algorithms and calculators
  • Keyword search functionality
  • Bookmarking and note-taking
  • News and push notifications
Features
Read full description

The European Society for Medical Oncology (ESMO) guidelines are developed by experts. They are concise, practical and offer users treatment recommendations that are based on the latest scientific research. This application uses interactive tools to support decision making and help the user navigate the guidelines easily, so they can access the information they require quickly. Each guideline offers best practice recommendations for screening, diagnosis, staging, treatment and follow up. The ESMO Interactive Guidelines application ensures the user has the highest standard of information at their figure tips. A variety of interactive treatment algorithms, tables, calculators and scores can be utilised to assist the treating doctor. The user can also perform key word searches, bookmark useful pages, add notes and email pages to colleagues or patients. The app features news and push notifications. Disclaimer: The app is intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using this app shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and shall be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient’s individual circumstances and needs. The app contains information obtained from authentic and highly regarded sources (http://www.esmo.org). Although every effort has been made to ensure that treatment and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician.This application is updated regularly with more tumour types, guidelines and interactive tools.

Screenshots

iURO Oncology4 screens
ESMO Interactive Guidelines4 screens

Verdict

The call

The clearest difference is review sentiment: ESMO Interactive Guidelines at 80% against iURO Oncology's 0%. ESMO Interactive Guidelines also leads on rating (4.8 vs 1.0) and in-app purchases (none vs 10). iURO Oncology's advantage is update cadence (every 2 months vs every 6 months) and iOS requirement (8.1 vs 12.0). On price, ads, monetization model and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. iURO Oncology sells 10 one-off in-app purchases. ESMO Interactive Guidelines asks for nothing beyond the download.

ReceptionRating · Positive reviews · Number of ratings

ESMO Interactive Guidelines holds the better App Store score, 4.8 against 1.0. That said, the two scores are not equally well evidenced: ESMO Interactive Guidelines has 150 ratings behind it against 1, so its average is the more settled of the two. Written reviews point the same way: 0% of iURO Oncology's written reviews are positive against 80% of ESMO Interactive Guidelines's.

UpkeepUpdate frequency

iURO Oncology ships an update every 2 months, ESMO Interactive Guidelines every 6 months. The most recent releases landed on October 5, 2026 and October 15, 2026 respectively.

Scorecard6 real differences · 4 level
iURO Oncology versus ESMO Interactive Guidelines: the parameters behind the verdict, then further details
ParameteriURO OncologyESMO Interactive Guidelines
PriceFreeFree
Rating1.0 (1 ratings)4.8 (150 ratings) — better
Positive reviews0.0% of reviews80.0% of reviews — better
Number of ratings1150 — better
Update frequencyEvery 2 months — betterEvery 6 months
AdsNoNo
In-app purchasesYesNo — better
MonetizationFreeFree
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS8.1 — better12.0
Further details — not scored
Size307 MB195 MB
Age rating17+12+
DeveloperURO DevelopmentsEuropean Society for Medical Oncology - ESMO

Customer experience

iURO Oncology

All ratings1 ratings
Positive0.0%
Neutral0.0%
Negative100.0%
Written reviews6 reviews
Positive0.0%
Neutral0.0%
Negative100.0%

ESMO Interactive Guidelines

All ratings150 ratings
Positive96.7%
Neutral2.0%
Negative1.3%
Written reviews5 reviews
Positive80.0%
Neutral0.0%
Negative20.0%

In-app purchases

10 purchases

iURO Oncology

One-time10
  • Renal Cancer$0.99
  • Non muscle invasive Bladder Cancer$0.99
  • Testis cancer$0.99
Show 7 more
  • Radical Inguinal Orchiectomy video$0.99
  • Radical Prostatectomy with Neurovascular bundle preservation video$0.99
  • Transurethral resection of bladder tumor TUR-B Video$0.99
  • Renal cancer interfase$0.99
  • Open Partial Nephrectomy$0.99
  • Therapies videos - Section 2$2.99
  • All of content$5.99
None

ESMO Interactive Guidelines

No in-app purchases

Questions

Is iURO Oncology free?
iURO Oncology is free to download, with in-app purchases available.
Is ESMO Interactive Guidelines free?
ESMO Interactive Guidelines is free to download, with no in-app purchases.
Which has better reviews, iURO Oncology or ESMO Interactive Guidelines?
ESMO Interactive Guidelines is rated higher. iURO Oncology averages 1.0 out of 5 from 1 ratings, while ESMO Interactive Guidelines averages 4.8 from 150 ratings.
Do iURO Oncology or ESMO Interactive Guidelines have ads?
Neither iURO Oncology nor ESMO Interactive Guidelines shows ads.
Which is updated more often, iURO Oncology or ESMO Interactive Guidelines?
iURO Oncology ships an update every 2 months, and ESMO Interactive Guidelines every 6 months. Most recently, iURO Oncology was updated on October 5, 2026 and ESMO Interactive Guidelines on October 15, 2026.

Other comparisons